JSKN-016
- Generic Name
- JSKN-016
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Inoperable Locally Advanced HER2-Negative Breast CancerMetastatic HER2-Negative Breast Cancer
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT06942234
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Phase 1
Not yet recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Furmonertinib Mesylate
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT06868732
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Phase 2
Not yet recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT06775483
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath